Abstracts tagged "Bone density"

Abstract Number: 373 • 2013 ACR/ARHP Annual Meeting
Menopause Occurs Earlier and Is An Independent Risk Factor For Osteoporosis In Women With Rheumatoid Arthritis
Michael Cocker¹, Alexander Oldroyd² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) and early menopause (
Abstract Number: 1979 • 2012 ACR/ARHP Annual Meeting
Care Gap in the Treatment of Patients with High Risk for Fractures in a Single Canadian Academic Center
Arthur N. Lau¹, Michael Branch², Robert Bensen³, Jonathan D. Adachi⁴, Alexandra Papaioannou⁵, William Wong-Pack⁶ and William G. Bensen⁷, ¹Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²CEO, Inovex, Oakville, ON, Canada, ³Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Geriatric Medicine, McMaster University, Hamilton, ON, Canada, ⁶Department Of Nuclear Medicine, Hamilton, ON, Canada, ⁷Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada
Background/Purpose: A number of clinical prediction tools are available to stratify patients into low, moderate and high risk for fractures in future. These tools are…
Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kazuhiko Hatta², Kuniki Amano³, Noriko Kuwaba⁴ and Hiroyuki Ohta⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Hatta Clinic, Kure, Japan, ³Rheumatology, Sky Clinic, Hiroshima, Japan, ⁴Medical Research, Sanki Clinical Link, Hiroshima, Japan, ⁵Medical Research, hiroshima clinic, Hiroshima, Japan
Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…
Abstract Number: 1985 • 2012 ACR/ARHP Annual Meeting
The Effect of Calcium and Vitamin D On Bone Loss in an Epileptic Population
Philip Dussault¹, Samuel Davis Jr.² and Antonio A. Lazzari³, ¹Primary Care / Pharmacy, Boston VA HCS, Boston, MA, ²Osteoporosis, Boston VA HCS, Boston, MA, ³Prim Care/Rheumatology, Boston VA Medical Center, Boston, MA
Background/Purpose: Accelerated rate of bone loss leading to osteopenia and osteoporosis is a well recognized adverse effect of long term anticonvulsant use, particularly phenytoin,…
Abstract Number: 1987 • 2012 ACR/ARHP Annual Meeting
A Comparison of Unilateral and Bilateral Hip BMD
Steven C. Schaub¹, Edward S. Leib² and Diantha Howard³, ¹Medical School, U of Vermont College of Med, Burlington, VT, ²Medicine, U of Vermont College of Med, Burlington, VT, ³Statistics, Vermont Center for Clinical and Translational Science, Burlington, VT
Background/Purpose: The utility of bilateral hip dual energy x-ray absorptiometry scanning for identifying low bone mineral density has been a cause of debate. Intraperson differences…
Abstract Number: 1989 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Vertebral Fractures in Patients with Rheumatoid Arthritis – the Tomorrow Study –
Tadashi Okano¹, Tatsuya Koike², Masahiro Tada¹, Kenji Mamoto³, Yuko Sugioka¹, Atsuko Kamiyama⁴ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Medical School, Osaka, Japan, ²Center for Senile Degenerative Disorders (CSDD), Osaka City University Medical School, Osaka, Japan, ³Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Rheumatosurgery, Osaka City University Medical School, Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is one of the causes for secondary osteoporosis. Osteoporosis as a multifactorial disease might be derived from comorbidity itself, poorer physical…
Abstract Number: 1992 • 2012 ACR/ARHP Annual Meeting
Anti-TNF Therapies Improve Bone Mineral Density At the Lumbar Spine of RA Patients by Decreasing Disease Activity and Suppressing Serum RANKL Levels
Allen P. Anandarajah¹, Jennifer Hossler², Kate Burns³, Kelly Callahan³, Yahui Grace Chiu³ and Jennifer H. Anolik⁴, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Rheumatology, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Generalized bone loss (osteoporosis or osteopenia) is more common in patients with rheumatoid arthritis (RA) than in the general population. Recent studies suggest that…
Abstract Number: 1996 • 2012 ACR/ARHP Annual Meeting
Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?
Marlies C. van der Goes¹, Johannes W.G. Jacobs¹, Maud S. Jurgens¹, Marije F. Bakker¹, Maaike J. van der Veen², Jacobine H. van der Werf³, Paco M.J. Welsing¹ and Johannes W.J. Bijlsma¹, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology, St. Jansdal hospital, Harderwijk, Netherlands, ³Rheumatology, Diakonessenhuis, Utrecht, Netherlands
Background/Purpose: To describe effects on bone mineral density (BMD) of treatment according to EULAR guidelines with a methotrexate-based tight control strategy including 10 mg prednisone…
Abstract Number: 1997 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Denosumab Vs Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates: A Randomized, Open-Label Study
Michael A. Bolognese¹, Edward Czerwinski², Henry G. Bone³, Sydney Bonnick⁴, Neil Binkley⁵, Alfred Moffett Jr.⁶, Suresh Siddhanti⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Rachel Wagman⁷, Jesse W. Hall⁷ and Chris Recknor¹⁰, ¹Bethesda Health Research Center, Bethesda, MD, ²Krakow Medical Center, Krakow, Poland, ³Michigan Bone and Mineral Clinic, Detroit, MI, ⁴Clinical Research Center of North Texas, Denton, TX, ⁵University of Wisconsin, Madison, WI, ⁶OB-GYN Associates of Mid Florida, PA, Leesburg, FL, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Background/Purpose: Denosumab, a fully human monoclonal antibody that specifically targets RANKL to inhibit osteoclast formation, function, and survival, reduces risk for vertebral, non-vertebral, and hip…
Abstract Number: 1998 • 2012 ACR/ARHP Annual Meeting
Relationship Between Changes in Bone Mineral Density and Incidence of Fracture with 6 Years of Denosumab Treatment
Michael A. Bolognese¹, Paul D. Miller², Jean-Yves Reginster³, Nathalie Franchimont⁴, Gerolamo Bianchi⁵, Roland Chapurlat⁶, Federico G. Hawkins⁷, David L. Kendler⁸, Beatriz Oliveri⁹, Jose R. Zanchetta¹⁰, Nadia Daizadeh⁴, Andrea Wang⁴, Rachel B. Wagman⁴ and Socrates Papapoulos¹¹, ¹Bethesda Health Research Center, Bethesda, MD, ²University of Colorado Health Sciences Center and Colorado Center for Bone Research, Lakewood, CO, ³Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ⁴Amgen Inc., Thousand Oaks, CA, ⁵LELICOMAR - Div Reumatologia, Azienda Sanitaria Genovese, Genoa, Italy, ⁶Hôpital Edouard Herriot, Lyon, France, ⁷Hospital Universitario, Madrid, Spain, ⁸University of British Columbia, Vancouver, BC, Canada, ⁹Laboratorio Enfermedades Metabólicas Oseas, Hospital de Clínicas, INIGEM UBA-CONICET, Buenos Aires, Argentina, ¹⁰Instituto de Investigaciones Metabólicas and University of Salvador, Buenos Aires, Argentina, ¹¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: During the first 3 years of denosumab treatment in FREEDOM, there were continued increases in bone mineral density (BMD) and a robust reduction in…
Abstract Number: 1970 • 2012 ACR/ARHP Annual Meeting
Utility of Spine Bone Mineral Density in Fracture Prediction within the Fracture Risk Assessment Tool (FRAX)
Tristan Blackburn¹, Diantha Howard² and Edward S. Leib³, ¹Rheumatology, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT, ²Medicine, Vermont Center for Clinical and Translational Science, Burlington, VT, ³Medicine, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Predicting which individuals are at risk to experience a fracture and modify that risk is important in preventative health. The WHO’s Fracture Risk Assesment…
Abstract Number: 1958 • 2012 ACR/ARHP Annual Meeting
Bone Mineral Density in Lupus Erythematosus Women One Year After Rituximab Therapy
Claudia Mendoza-Pinto¹, Mario Garcia-Carrasco¹, Mario Jiménez-Hernández¹, Alma Rodríguez-Gallegos², Socorro Méndez-Martínez¹ and Aurelio Lopez-Colombo³, ¹Systemic Autoimmune Disease, HGR 36 CMN Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Laboratorios Clínicos de Puebla, Puebla, Mexico, ³Research Departament, Delegación Estatal, Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Low bone mineral density (BMD) and osteoporosis may be significant complications in patients with systemic lupus erythematosus (SLE). Recent studies have shown that biologic therapy could…
Abstract Number: 1557 • 2012 ACR/ARHP Annual Meeting
What Percentage of Postmenopausal Women Younger Than Age 65 Years Have Low Bone Mineral Density At a Family Health Center?
Marvin Vaishnani¹ and Feyrouz T. Al-Ashkar², ¹Rheumatic and Immunologic diseases, Cleveland Clinic,Lorain Institute, Lorain, OH, ²Rheumatic and Immunologic Diseases, Cleveland Clinic,Lorain Institute, Lorain, OH
Background/Purpose: Many younger women, < 65 years of age may have low bone mineral density (BMD) that remains undetected in clinical practice due to following…
Abstract Number: 1226 • 2012 ACR/ARHP Annual Meeting
Transition Time to Osteoporosis in Patients with Rheumatoid Arthritis
Jiwon Hwang¹, Joong Kyong Ahn², Ji Young Chai³, Hoon-Suk Cha¹, Jaejoon Lee¹ and Eunmi Koh¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Division of Rheumatology, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea
Background/Purpose: Rheumatoid arthritis (RA) is an independent risk factor for osteoporosis. Although bone mineral density (BMD) testing is routinely performed in patients with RA, the…
Abstract Number: 2583 • 2012 ACR/ARHP Annual Meeting
Bone Structure and Perfusion Quantification of Bone Marrow Edema and Pannus Tissue Areas in the Wrist of Patients with RA
Jose R. Teruel Antolin¹, Andrew J. Burghardt², Julien Rivoire¹, Waraporn Srikhum¹, Susan M. Noworolski³, Thomas M. Link¹, John B. Imboden⁴ and Xiaojuan Li⁵, ¹Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ²Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ³Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA, ⁵Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA
Background/Purpose: Bone marrow edema (BME) has been suggested as a strong predictor for erosive progression in RA joints, however, no previous studies examined the bone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].